BACKGROUND: We explored the safety and efficacy of ablative doses of stereotactic body radiation therapy (SBRT) for unresectable pancreatic cancer. METHODS: This phase I/II trial included patients with unresectable pancreatic cancer previously treated with any number of cycles of induction chemotherapy. Patients were enrolled according to a 3+3 dose escalation design at 10, 12.5, and 15 Gy ×3, with subsequent patients at the maximally tolerated dose (MTD). Treatment was delivered to gross tumor delineated with MRI fusion using image-guidance to fiducial markers. Dose-limiting toxicity (DLT) was defined as grade 3+ toxicity within 30 days. Secondary endpoints included late gastrointestinal (GI) toxicity, freedom from local failure (FFLF), and survival. RESULTS: Fifteen patients received a median 10 cycles of chemotherapy. There were no DLTs, and the MTD was 15 Gy ×3. Thirty-day toxicity included grade 2 nausea (46%) and grade 2 diarrhea (7%). Median survival after SBRT was 12.8 months (23 months after diagnosis) and median relapse-free survival was 7 months. At 1-year, FFLF was 80%. Four patients had grade 3+ GI bleeding after 30 days (median 6 months). Grade 3+ GI bleeding was associated with tumor volume (P=0.01), heterogeneity of dose within the planning target volume (PTV) (V120, P=0.03), and duodenal dose (V26-30 Gy, P<0.2). CONCLUSIONS: This aggressive SBRT regimen demonstrated limited 30-day morbidity, a moderate degree of local control, and a moderate risk for late GI bleeding. Further work is necessary to define the most appropriate hypofractionated radiation therapy (RT) regimen in the ablative dose range. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: We explored the safety and efficacy of ablative doses of stereotactic body radiation therapy (SBRT) for unresectable pancreatic cancer. METHODS: This phase I/II trial included patients with unresectable pancreatic cancer previously treated with any number of cycles of induction chemotherapy. Patients were enrolled according to a 3+3 dose escalation design at 10, 12.5, and 15 Gy ×3, with subsequent patients at the maximally tolerated dose (MTD). Treatment was delivered to gross tumor delineated with MRI fusion using image-guidance to fiducial markers. Dose-limiting toxicity (DLT) was defined as grade 3+ toxicity within 30 days. Secondary endpoints included late gastrointestinal (GI) toxicity, freedom from local failure (FFLF), and survival. RESULTS: Fifteen patients received a median 10 cycles of chemotherapy. There were no DLTs, and the MTD was 15 Gy ×3. Thirty-day toxicity included grade 2 nausea (46%) and grade 2 diarrhea (7%). Median survival after SBRT was 12.8 months (23 months after diagnosis) and median relapse-free survival was 7 months. At 1-year, FFLF was 80%. Four patients had grade 3+ GI bleeding after 30 days (median 6 months). Grade 3+ GI bleeding was associated with tumor volume (P=0.01), heterogeneity of dose within the planning target volume (PTV) (V120, P=0.03), and duodenal dose (V26-30 Gy, P<0.2). CONCLUSIONS: This aggressive SBRT regimen demonstrated limited 30-day morbidity, a moderate degree of local control, and a moderate risk for late GI bleeding. Further work is necessary to define the most appropriate hypofractionated radiation therapy (RT) regimen in the ablative dose range. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Edward P Balaban; Pamela B Mangu; Alok A Khorana; Manish A Shah; Somnath Mukherjee; Christopher H Crane; Milind M Javle; Jennifer R Eads; Peter Allen; Andrew H Ko; Anitra Engebretson; Joseph M Herman; John H Strickler; Al B Benson; Susan Urba; Nelson S Yee Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Joseph K Salama; Steven J Chmura; Neil Mehta; Kamil M Yenice; Walter M Stadler; Everett E Vokes; Daniel J Haraf; Samuel Hellman; Ralph R Weichselbaum Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: Mary Feng; James M Balter; Daniel Normolle; Saroja Adusumilli; Yue Cao; Thomas L Chenevert; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-22 Impact factor: 7.038
Authors: Tiziana Comito; L Cozzi; E Clerici; C Franzese; A Tozzi; C Iftode; P Navarria; G D'Agostino; L Rimassa; C Carnaghi; N Personeni; M C Tronconi; F De Rose; D Franceschini; A M Ascolese; A Fogliata; S Tomatis; A Santoro; A Zerbi; M Scorsetti Journal: Technol Cancer Res Treat Date: 2016-06-16
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Abhinav V Reddy; Shuchi Sehgal; Colin S Hill; Lei Zheng; Jin He; Joseph M Herman; Jeffrey Meyer; Amol K Narang Journal: Curr Oncol Date: 2022-01-11 Impact factor: 3.677